Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Manuela RabaglioZhuoxin SunRudolf MaibachAnita Giobbie-HurderBent EjlertsenVernon J HarveyPatrick NevenIstván LángHervé BonnefoiAndrew WardleyBarbara RueppMonica CastiglioneAlan S CoatesRichard D GelberAron GoldhirschMarco ColleoniBeat ThürlimannMeredith M ReganPublished in: Breast cancer research and treatment (2020)
When initiating or switching between adjuvant endocrine treatments in postmenopausal patients, age and medical history, with special attention to prior cardiovascular events, should be balanced with expected benefit of the treatment.
Keyphrases
- cardiovascular events
- coronary artery disease
- cardiovascular disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- healthcare
- chronic kidney disease
- clinical trial
- peritoneal dialysis
- risk factors
- working memory
- prognostic factors
- randomized controlled trial
- phase ii
- machine learning
- polycystic ovary syndrome
- body composition
- breast cancer cells
- skeletal muscle
- amino acid
- open label
- artificial intelligence
- insulin resistance
- placebo controlled